Founded in 2007, C2 Therapeutics is the developer for the CryoBalloon Ablation technology to treat Barrett’s Esophagus and squamous dysplasia.
The device is intended to be used as a cryosurgical tool in the field of general surgery, particularly for endoscopic applications, to include endoscopic ablation of Barrett’s Esophagus with high grade dysplasia.
The through-the-scope, highly compliant balloon catheter, after being inserted, assumes the shape of the esophageal lumen without creating additional tension on the esophageal wall.
It then allows delivery of targeted dose of cryogen for an immediate ablation of the targeted tissues.
Barrett’s esophagus and squamous dysplasia are characterised with an abnormally changed epithelial cells in the lining of the esophagus to form pre-cursor lesions.
These lesions can trigger esophageal cancer in some patients if left unattended.
PENTAX Medical global chief marketing officer David Woods said: “The C2 CryoBalloon Ablation System has the potential to improve the lives of millions of people around the world with pre-cancerous lesions of the esophagus.
“We plan to continue working with thought leaders from around the world to further develop the C2 CryoBalloon Ablation System and commercialise the technology with clinically relevant strategies that meet the therapeutic and economic needs of these targeted patient populations”.
The acquisition is expected to boost Pentax Medical’s therapeutic endoscopy portfolio with the addition of the C2 CryoBalloon Ablation System as well as extend company’s role from being a provider of advanced imaging for diagnostics to providing advanced therapeutic solutions as well.